This article features a Q&A with Jonathan Andrus, Chief Business Officer at Clinical Ink, and appeared in the October 29, 2019, issue of The Evidence Base.
In this article, you’ll learn:
- The importance of RWE in regulatory decision making
- How RWE challenges quality and compliance programs
- How the employment of RWE will change in the future